Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV Co-Infected Patients: Implications for Treatment Outcomes

Journal of Hepatology - Netherlands
doi 10.1016/j.jhep.2010.03.019
Full Text
Abstract

Available in full text

Categories
Hepatology
Date
Authors
Publisher

Elsevier BV

Related search

SVR Rates of HCV-infected Population Under PEG-IFN-α/R Treatment in Northwest China

Virology Journal
VirologyInfectious Diseases
2017English

Therapeutic Response to Peg-Ifn-Alpha-2b and Ribavirin in HIV/HCV Co-Infected African-American and Caucasian Patients as a Function of HCV Viral Kinetics and Interferon Pharmacodynamics

AIDS
Infectious DiseasesAllergyImmunology
2009English

Changes in Immune Activation in the T Cell Compartments of HIV HCV Coinfected Patients During PEG IFN RBV Treatment

Retrovirology
VirologyInfectious Diseases
2012English

Correction of Metabolic Disorders in Patients Co-Infected With HIV/HCV

ScienceRise
2015English

The Change of Quantitative of HBeAg Can Predict the Efficacy of Peg-Ifn-Α 2a in HBeAgpositive CHB Patients

Infection International
2013English

Survival of HIV/HCV Co-Infected Patients Before Introduction of HCV Direct Acting Antivirals (DAA)

Scientific Reports
Multidisciplinary
2019English

Changes of Body Immunity and Inflammatory Response in HIV/HCV Co-Infected Patients

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2018English

Provider and Patient Correlates of Provider Decisions to Recommend HCV Treatment to HIV Co-Infected Patients

Journal of the International Association of Physicians in AIDS Care
2012English

PHS60 Health-Related Quality of Life in HIV/HCV Co-Infected Patients in Ireland

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy